2021
Association of Cannabis Use During Adolescence With Neurodevelopment
Albaugh MD, Ottino-Gonzalez J, Sidwell A, Lepage C, Juliano A, Owens MM, Chaarani B, Spechler P, Fontaine N, Rioux P, Lewis L, Jeon S, Evans A, D’Souza D, Radhakrishnan R, Banaschewski T, Bokde ALW, Quinlan EB, Conrod P, Desrivières S, Flor H, Grigis A, Gowland P, Heinz A, Ittermann B, Martinot JL, Martinot M, Nees F, Orfanos D, Paus T, Poustka L, Millenet S, Fröhner JH, Smolka MN, Walter H, Whelan R, Schumann G, Potter A, Garavan H. Association of Cannabis Use During Adolescence With Neurodevelopment. JAMA Psychiatry 2021, 78: 1031-1040. PMID: 34132750, PMCID: PMC8209561, DOI: 10.1001/jamapsychiatry.2021.1258.Peer-Reviewed Original ResearchCannabis useAltered neurodevelopmentAge-related cortical thinningBaseline cortical thicknessAge-related thinningDose-dependent fashionRight prefrontal cortexMR imagesEuropean School Survey ProjectCortical thickness developmentCohort studyCortical thinningStudy baselineCIVET pipelineEndocannabinoid signalingMAIN OUTCOMECortical thicknessAdolescent brain developmentAnimal studiesSignificant associationBrain developmentPrefrontal cortexAdolescent brainBehavioral effectsCortex
2015
The Formation of Marijuana Risk Perception in a Population of Substance Abusing Patients
Wilkinson ST, van Schalkwyk GI, Davidson L, D’Souza D. The Formation of Marijuana Risk Perception in a Population of Substance Abusing Patients. Psychiatric Quarterly 2015, 87: 177-187. PMID: 25982082, DOI: 10.1007/s11126-015-9369-z.Peer-Reviewed Original ResearchConceptsRisk perceptionSubstance usersIndividual experiencesSample of substanceNegative social consequencesSubstance abuse problemsMarijuana risk perceptionsInductive thematic analysisMarijuana useSemi-structured interviewsPhysical withdrawalSubstance abuseAbuse problemsPerceptionSocial consequencesBehavioral effectsMarijuanaOvert behavioral effectsThematic analysisProminent perspectivesSources of informationParticipantsVeteransExperiencePrevious literatureΔ9-THC Disrupts Gamma (γ)-Band Neural Oscillations in Humans
Cortes-Briones J, Skosnik PD, Mathalon D, Cahill J, Pittman B, Williams A, Sewell RA, Ranganathan M, Roach B, Ford J, D'Souza DC. Δ9-THC Disrupts Gamma (γ)-Band Neural Oscillations in Humans. Neuropsychopharmacology 2015, 40: 2124-2134. PMID: 25709097, PMCID: PMC4613601, DOI: 10.1038/npp.2015.53.Peer-Reviewed Original ResearchConceptsAuditory steady-state responseΔ9-THCHz stimulationIntertrial coherenceDose-related effectsNeural oscillationsNegative Syndrome ScalePsychophysiological alterationsAcute effectsPsychotic disordersAnimal studiesSyndrome ScalePANSS subscalesRecent usersBehavioral effectsTotal scoreEvoked powerCannabinoidsCounterbalanced designTrend levelΓ oscillationsTest dayBand oscillationsHz conditionStimulation
2014
Effects of Nicotine on the Neurophysiological and Behavioral Effects of Ketamine in Humans
Mathalon DH, Ahn KH, Perry EB, Cho HS, Roach BJ, Blais RK, Bhakta S, Ranganathan M, Ford JM, D’Souza D. Effects of Nicotine on the Neurophysiological and Behavioral Effects of Ketamine in Humans. Frontiers In Psychiatry 2014, 5: 3. PMID: 24478731, PMCID: PMC3900858, DOI: 10.3389/fpsyt.2014.00003.Peer-Reviewed Original ResearchAuditory event-related brain potentialsEvent-related brain potentialsTest sessionsBehavioral effectsAmplitude of P3aDissociative Symptoms ScaleNicotinic acetylcholine receptor stimulationBrain potentialsP3b amplitudeMMN amplitudeP3a amplitudeNovel stimuliNeurophysiological measuresNMDA receptor hypofunctionN-methyl-D-aspartate (NMDA) receptor hypofunctionNegative Syndrome ScaleEffects of nicotineReceptor hypofunctionNeurocognitive impairmentCounterbalanced mannerP3aSchizophrenia-like effectsSyndrome ScaleInjections of nicotineInteraction of ketamine
2012
Nicotine Fails to Attenuate Ketamine-Induced Cognitive Deficits and Negative and Positive Symptoms in Humans: Implications for Schizophrenia
D'Souza DC, Ahn K, Bhakta S, Elander J, Singh N, Nadim H, Jatlow P, Suckow RF, Pittman B, Ranganathan M. Nicotine Fails to Attenuate Ketamine-Induced Cognitive Deficits and Negative and Positive Symptoms in Humans: Implications for Schizophrenia. Biological Psychiatry 2012, 72: 785-794. PMID: 22717030, DOI: 10.1016/j.biopsych.2012.05.009.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAttentionCognitionCognition DisordersCross-Over StudiesDouble-Blind MethodDrug InteractionsExecutive FunctionHumansInhibition, PsychologicalKetamineMemoryMiddle AgedMotor SkillsNicotinePsychiatric Status Rating ScalesPsychomotor PerformanceReaction TimeRecognition, PsychologySchizophreniaConceptsCognitive deficitsPositive symptomsExecutive functionResponse inhibitionKetamine-induced cognitive deficitsChoice reaction time taskSpeed of processingReaction time taskReaction timeVisual memoryEmotion recognitionImmediate recallSustained attentionTime taskFeeling statesPerceptual alterationsSerial processingEffects of nicotineNegative symptomsMemoryBehavioral effectsDeficitsInteractive effectsNicotine infusionTest day
2008
Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of Δ-9-tetrahydrocannabinol in humans
D’Souza D, Braley G, Blaise R, Vendetti M, Oliver S, Pittman B, Ranganathan M, Bhakta S, Zimolo Z, Cooper T, Perry E. Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of Δ-9-tetrahydrocannabinol in humans. Psychopharmacology 2008, 198: 587-603. PMID: 18228005, PMCID: PMC2878815, DOI: 10.1007/s00213-007-1042-2.Peer-Reviewed Original ResearchConceptsPerceptual alterationsPsychotomimetic effectsCambridge taskRecall deficitsVerbal recallSample taskCognitive effectsMemory impairmentCognitive impairmentSubjective effectsPreclinical literatureBehavioral effectsTaskD2 receptor mechanismsEffects of haloperidolFrequent usersDopaminergic systemHaloperidol pretreatmentImpairmentDistractibilityRecallResultsConsistentSpectrum of effectsRandom orderDeficits
2005
Absence of behavioral sensitization in healthy human subjects following repeated exposure to ketamine
Cho HS, D’Souza D, Gueorguieva R, Perry EB, Madonick S, Karper LP, Abi-Dargham A, Belger A, Abi-Saab W, Lipschitz D, Bennet A, Seibyl JP, Krystal JH. Absence of behavioral sensitization in healthy human subjects following repeated exposure to ketamine. Psychopharmacology 2005, 179: 136-143. PMID: 15682309, DOI: 10.1007/s00213-004-2066-5.Peer-Reviewed Original ResearchConceptsHealthy human subjectsBehavioral sensitizationReceptor antagonistN-methyl-D-aspartate (NMDA) glutamate receptor antagonistBehavioral effectsHuman subjectsGlutamate receptor antagonistsNMDA receptor antagonistConclusionsThe current dataEvidence of sensitizationRetrospective studyKetamine administrationOutcome measuresNegative symptomsObjectivesThe purposePrevious exposureFirst exposureKetamineSensitizationAntagonistExposurePerceptual alterationsCurrent dataSeparate studiesSubjects
2003
N-methyl-d-aspartate glutamate receptors and alcoholism: reward, dependence, treatment, and vulnerability
Krystal JH, Petrakis IL, Mason G, Trevisan L, D'Souza DC. N-methyl-d-aspartate glutamate receptors and alcoholism: reward, dependence, treatment, and vulnerability. Pharmacology & Therapeutics 2003, 99: 79-94. PMID: 12804700, DOI: 10.1016/s0163-7258(03)00054-8.Peer-Reviewed Original ResearchConceptsGlutamatergic systemEthanol abuseGlutamate receptorsN-methyl-D-aspartate (NMDA) subtypePrimary excitatory neurotransmitterAspartate glutamate receptorsAction of ethanolEthanol withdrawalGlutamatergic agentsGlutamatergic functionExcitatory neurotransmitterTranslational neuroscience perspectiveGlutamate systemEthanol intoxicationBehavioral effectsEthanol contributeAlcoholismBrainReceptorsTreatmentAbuseN-methylSubtypesNeurotransmittersIntoxication
1998
Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans
Krystal J, Karper L, Bennett A, D’Souza D, Abi-Dargham A, Morrissey K, Abi-Saab D, Bremner J, Bowers Jr. M, Suckow R, Stetson P, Heninger G, Charney D. Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans. Psychopharmacology 1998, 135: 213-229. PMID: 9498724, DOI: 10.1007/s002130050503.Peer-Reviewed Original ResearchConceptsWisconsin Card Sorting TestClinician-Administered Dissociative States ScalePerceptual alterationsAmnestic effectsInteractive effectsCard Sorting TestBrief Psychiatric Rating ScaleAttention impairmentSorting TestPerceptual effectsProverb interpretationEmotional distressDissociative effectsCortical impairmentNegative symptomsState scaleBehavioral effectsTest dayPsychiatric Rating ScaleLorazepam 2ImpairmentRating ScaleSubanesthetic ketamineHealthy humansPlacebo 2